Comments
Loading...

Summit Therapeutics

SMMTNASDAQ
Logo brought to you by Benzinga Data
$25.03
0.471.91%
Pre-Market: 4:51 AM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$45.00
Lowest Price Target1
$19.00
Consensus Price Target1
$29.67

Summit Therapeutics (NASDAQ:SMMT) Stock, Analyst Ratings, Price Targets, Forecasts

Summit Therapeutics Inc has a consensus price target of $29.67 based on the ratings of 3 analysts. The high is $45 issued by HC Wainwright & Co. on September 17, 2024. The low is $19 issued by Citigroup on September 9, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Citigroup on September 17, 2024, September 16, 2024, and September 9, 2024, respectively. With an average price target of $36.33 between HC Wainwright & Co., HC Wainwright & Co., and Citigroup, there's an implied 45.16% upside for Summit Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
May
0
0
0
0
Jun
0
0
0
0
Aug
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Citigroup
Stifel

1calculated from analyst ratings

Analyst Ratings for Summit Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Summit Therapeutics (SMMT) stock?

A

The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by HC Wainwright & Co. on September 17, 2024. The analyst firm set a price target for $45.00 expecting SMMT to rise to within 12 months (a possible 79.78% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Summit Therapeutics (SMMT)?

A

The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by HC Wainwright & Co., and Summit Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Summit Therapeutics (SMMT)?

A

There is no last upgrade for Summit Therapeutics

Q

When was the last downgrade for Summit Therapeutics (SMMT)?

A

There is no last downgrade for Summit Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Summit Therapeutics (SMMT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.

Q

Is the Analyst Rating Summit Therapeutics (SMMT) correct?

A

While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a reiterated with a price target of $45.00 to $45.00. The current price Summit Therapeutics (SMMT) is trading at is $25.03, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch